Category: Press Releases

Mark A. Goldberg, MD, Joins Intensity Therapeutics, Inc. Board of Directors

Intensity Therapeutics, Inc., a privately held biotechnology company developing proprietary cancer immune-based drug products for direct intratumoral injection, today announced that Mark A. Goldberg, MD has been appointed to the Company’s Board of Directors effective May 1, 2018. Dr. Mark A. Goldberg recently served as president and COO of PAREXEL International, one of the world’s… Read more »

Intensity Therapeutics, Inc. Reports Positive Safety Data from On-going IT-01 Phase 1/2 Trial

Intensity Therapeutics, Inc., a privately held biotechnology company developing proprietary cancer immune-based drug products for direct intratumoral injection, today announced completion of the first safety cohort (A) of the Company’s Phase 1/2 international clinical study evaluating lead product, INT230-6. Following intratumoral drug injections into superficial lesions in six patients with either ovarian, thyroid, head and… Read more »

Intensity Therapeutics Invited to Speak and Present at Upcoming Conferences

Intensity Therapeutics, Inc., a privately held clinical-stage, biotechnology company developing proprietary cancer immune-based products, today announced that President and CEO Lewis H. Bender would be speaking on a CEO Panel titled: Raising Capital in the Current Market during the Immuno-Oncology 360° conference at the Roosevelt Hotel in New York City, NY February 7-9, 2018. IO360… Read more »

Intensity Therapeutics Issued New Patents for Technology Platform

Intensity Therapeutics, Inc., a privately held clinical-stage, biotechnology company developing proprietary cancer immunotherapy products, today announced that the United States Patent and Trademark Office (PTO) issued the Company patent 9,636,406. In addition, the Company noted that the Australian PTO intends to grant Intensity patent 2013318338. “Intensity’s DfuseRxSM platform has identified our lead drug, INT230-6. This… Read more »

Intensity Therapeutics, Inc. Successfully Administers INT230-6 to First Patient in a Phase 1/2 Trial

Intensity Therapeutics, Inc., a privately held biotechnology company developing proprietary cancer immunotherapy products, today announced that the first patient successfully received treatment with the Company’s lead product, INT230-6, as part of a Phase 1/2 international clinical study. Initiation of the study followed acceptance of an investigational new drug (IND) submission by the US Food and… Read more »

Intensity Therapeutics reports that INT230-6 Induces Protective T-Cell Immunity in preclinical models

Intensity Therapeutics, Inc., a privately held biotechnology company developing proprietary immune cell-activating cancer treatments, announced that tumor regression and immune activation data generated by the Company’s lead drug, INT230-6, will be presented in a poster session at the American Academy of Cancer Research (AACR) meeting on April 5, 2017. The research being presented indicates that… Read more »

Intensity Therapeutics, Inc. Raises $10 Million to Fund Clinical Supplies Manufacturing and Phase I/II Trials of INT230-6

Intensity Therapeutics, Inc., a privately held biotechnology company developing proprietary cancer immunotherapy products, today announced that it has secured $10 million in new capital from a Series A preferred stock financing. Participants included Batterson Venture Capital, VCapital, FastForward Innovations, SalvaRx Group PLC, Declan Doogan M.D. and Jim Mellon as well as several other accredited investors… Read more »

Intensity Therapeutics Issued First US Patent for Immune-based Cancer Therapeutic Agents

Intensity Therapeutics, Inc., a privately held biotechnology company developing proprietary cancer immunotherapy products, today announced that the United States Patent and Trademark Office issued the Company US Patent 9,351,997. “Intensity’s DfuseRxSM platform technology has identified our lead drug, INT230-6. This novel product has shown great promise in regressing tumors and extending life in murine models… Read more »

Intensity Therapeutics reports that INT230-6’s Anti-cancer Mechanism is a Combination of Cell Death with Immune System Activation

Intensity Therapeutics, Inc., a privately held biotechnology company developing proprietary immune cell-activating cancer treatments, announced that Chief Medical Officer Dr. Ian B Walters will be presenting mechanism of action and other data in a poster session at the American Academy of Cancer Research (AACR) meeting on April 19, 2016. The research being presented indicates that… Read more »

Intensity Therapeutics Reports anti-Cancer Immunological Effect Generated by INT230-6

Intensity Therapeutics, Inc., a privately-held biotechnology company developing proprietary immune cell-activating cancer treatments, announced that preclinical research from the Company and its collaborators at the National Cancer Institute (NCI) were selected for oral presentation at two important upcoming congresses. The results demonstrate the ability of Intensity’s proprietary product, INT230-6, to create a robust anti-cancer immunological… Read more »